By Tim Boreham
Publication Date: 2025-12-11 02:12:00
Argentina has turned to artificial intelligence to save the actual brain power of severe stroke victims. Image: Getty Images
- Argentica’s stroke drug candidate appears to be able to reduce infarcts (brain loss) in more severe cases
- Major U.S. hospital leaders support Pro Medicus imaging products
- Neurizon launches Healey process after key approvals
After the company used AI for a second look at its Phase II ischemic stroke trial that disappointed investors, Argentica Therapeutics (ASX:AGN) is planning a more targeted follow-up study.
The company’s drug candidate ARG-007 does seem to work – albeit in more serious cases.
ARG-007 aims to reduce brain tissue death (infarction) after a stroke.
In early September, Argentica announced that the study had met its primary endpoint of safety and tolerability.
But the trial missed the secondary endpoint of effectiveness and Argentica shares fell 70%.
At that time, CEO Dr. Liz Dallimore that the therapy seemed to be effective…